JP2019529433A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529433A5
JP2019529433A5 JP2019515291A JP2019515291A JP2019529433A5 JP 2019529433 A5 JP2019529433 A5 JP 2019529433A5 JP 2019515291 A JP2019515291 A JP 2019515291A JP 2019515291 A JP2019515291 A JP 2019515291A JP 2019529433 A5 JP2019529433 A5 JP 2019529433A5
Authority
JP
Japan
Prior art keywords
rirotomabu
satetorakisetan
administration
lymphoma
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019515291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529433A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/073336 external-priority patent/WO2018050851A1/en
Publication of JP2019529433A publication Critical patent/JP2019529433A/ja
Publication of JP2019529433A5 publication Critical patent/JP2019529433A5/ja
Pending legal-status Critical Current

Links

JP2019515291A 2016-09-16 2017-09-15 リロトマブおよび177Lu‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法 Pending JP2019529433A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP16189191 2016-09-16
EP16189191.6 2016-09-16
EP17164164.0 2017-03-31
EP17164164 2017-03-31
EP17170641 2017-05-11
EP17170641.9 2017-05-11
EP17175768.5 2017-06-13
EP17175768 2017-06-13
PCT/EP2017/073336 WO2018050851A1 (en) 2016-09-16 2017-09-15 Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan

Publications (2)

Publication Number Publication Date
JP2019529433A JP2019529433A (ja) 2019-10-17
JP2019529433A5 true JP2019529433A5 (cg-RX-API-DMAC7.html) 2020-10-22

Family

ID=59895313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515291A Pending JP2019529433A (ja) 2016-09-16 2017-09-15 リロトマブおよび177Lu‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法

Country Status (14)

Country Link
US (2) US20190192703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3512881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019529433A (cg-RX-API-DMAC7.html)
KR (1) KR20190054113A (cg-RX-API-DMAC7.html)
CN (1) CN109790219A (cg-RX-API-DMAC7.html)
AU (1) AU2017327772A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019004838A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035268A1 (cg-RX-API-DMAC7.html)
IL (1) IL265387A (cg-RX-API-DMAC7.html)
MX (1) MX2019003029A (cg-RX-API-DMAC7.html)
PH (1) PH12019550033A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019110955A (cg-RX-API-DMAC7.html)
SG (2) SG10202102588QA (cg-RX-API-DMAC7.html)
WO (1) WO2018050851A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102688509B1 (ko) * 2017-08-04 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
US20210106703A1 (en) * 2017-11-22 2021-04-15 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
KR20240083769A (ko) 2022-12-05 2024-06-12 김원석 휴대할 수 있는 해수 정화 유닛용 물통

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101259270A (zh) * 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
CN109276713A (zh) * 2011-12-13 2019-01-29 诺帝克纳诺维科特股份公司 嵌合的治疗性抗-cd37抗体hh1
AU2016222887B2 (en) * 2015-02-24 2022-07-14 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof

Similar Documents

Publication Publication Date Title
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
JP2017008088A5 (cg-RX-API-DMAC7.html)
JP2016539156A5 (cg-RX-API-DMAC7.html)
PH12015502317A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
NZ609201A (en) Means and methods for treating dlbcl
JP2008519047A5 (cg-RX-API-DMAC7.html)
MY164352A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
RU2012157805A (ru) Способы лечения рака мочевого пузыря
RU2013102398A (ru) Лечение рака крови
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
MY173881A (en) Oral dosage forms of bendamustine and therapeutic use thereof
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
McCarthy et al. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer
MX2013010770A (es) Tratamiento de tumores solidos.
RU2017134443A (ru) Способ лечения с применением традипитанта
RU2019107011A (ru) Композиции апилимода и способы их применения
AR047988A1 (es) Combinaciones antineoplásicas de cci-779 y rituximab
JP2019529433A5 (cg-RX-API-DMAC7.html)
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
JP2016515619A5 (cg-RX-API-DMAC7.html)
RU2015145997A (ru) Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
ATE543492T1 (de) Behandlung von lungenkrebs